Skip to content

Geron GERN Total Liabilities

Total Liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$66.37B-11.5%
Incyte logo
IncyteINCY
$1.72B-17.6%
Immunome logo
ImmunomeIMNM
$31.11M-12.5%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$431.05M+1.3%
Celcuity logo
CelcuityCELC
$356.64M+171%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$44.29M-58.8%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$888.51M-8.6%
Enterprise value$973.78M-6.2%
P/S4.7×-174×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesFairValueDisclosure.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's total liabilities?
Geron (GERN) reported total liabilities of $129.77M in Q1 2026.
What is the long-term trend for Geron's total liabilities?
Over 5 years (2020 to 2025), Geron's total liabilities has grown at a 16.7% compound annual growth rate (CAGR), from $59.78M to $129.58M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.